Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of autoimmune diseases
3.2.1.2 Expansion of therapeutic indications
3.2.1.3 Advancements in biotechnology and drug development
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Patent analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Adalimumab
5.2.1 Branded
5.2.2 Biosimilar
5.3 Etanercept
5.3.1 Branded
5.3.2 Biosimilar
5.4 Infliximab
5.4.1 Branded
5.4.2 Biosimilar
5.5 Golimumab
5.6 Certolizumab pegol
Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Rheumatoid arthritis
6.3 Psoriasis
6.4 Psoriatic arthritis
6.5 Crohn’s disease
6.6 Ulcerative colitis
6.7 Ankylosing spondylitis
6.8 Juvenile idiopathic arthritis
6.9 Hidradenitis suppurativa
6.10 Other indications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Subcutaneous injection
7.3 Intravenous injection
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Amgen Inc.
10.3 Boehringer Ingelheim Pharmaceuticals, Inc.
10.4 Bio-Thera Solutions, Ltd.
10.5 Janssen Biotech, Inc.
10.6 Merck & Co., Inc.
10.7 Pfizer Inc.
10.8 Samsung Bioepis Co., Ltd.
10.9 Sandoz Group AG
10.10 UCB, Inc.
